Karyopharm Therapeutics Inc. (KPTI) Free cash flow 2016–2025
Karyopharm Therapeutics Inc. (KPTI) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$75.4MFY2025 · since FY2016: -$84.5M → -$75.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$75.4M | +40.9% |
| FY2024 | -$127.6M | -37.6% |
| FY2023 | -$92.7M | +38.0% |
| FY2022 | -$149.7M | -39.5% |
| FY2021 | -$107.3M | +33.1% |
| FY2020 | -$160.4M | +16.0% |
| FY2019 | -$191.0M | -18.3% |
| FY2018 | -$161.5M | -118.9% |
| FY2017 | -$73.8M | +12.6% |
| FY2016 | -$84.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More KPTI financial trends
KPTI RevenueKPTI Net incomeKPTI Net marginKPTI Gross profitKPTI Gross marginKPTI Operating incomeKPTI Operating marginKPTI Operating cash flowKPTI Capital expendituresKPTI Return on equityKPTI Stock buybacksKPTI Dividends paidKPTI Total assetsKPTI Total liabilitiesKPTI Shareholders’ equityKPTI overview →